RSS   Newsletter   Contact   Advertise with us

Senesco Technologies to buy biotechnology company Fabrus, Inc.

Share on Twitter Share on LinkedIn
Staff writer ▼ | May 20, 2014
Senesco Technologies, Inc. completed its acquisition of Fabrus, Inc., a biotechnology company focused on expanding the clinical impact of antibodies by addressing drug targets resistant to traditional antibody discovery methods.
Fabrus
FabrusSenesco Technologies, Inc. completed its acquisition of Fabrus, Inc., a biotechnology company focused on expanding the clinical impact of antibodies by addressing drug targets resistant to traditional antibody discovery methods.


Fabrus has been successful in generating antibodies against very difficult, therapeutically important cell surface receptors and ion channels resulting in an internal pipeline that includes next generation antibodies targeting cancer and inflammation.

It also has collaborations in place with large pharma and biotech companies to discover antibodies to their targets. Dr. Vaughn V. Smider, founder of Fabrus and faculty member at The Scripps Research Institute in La Jolla, CA, will become acting CEO of Senesco.

"In addition to our lead candidate currently in Phase 1b/2a development,, whose next step could be a Phase 2 clinical study, the combined organization has complementary technology platforms with the potential to bring multiple new candidates to the IND stage over the next two years," stated Leslie J. Browne, president of Senesco. "I am also pleased that Dr. Smider will be able to take over as acting CEO while I step down to manage ongoing health issues."

The business focus in the short term will be to realize the synergies of the combination by integrating our teams, advancing the SNS01-T clinical program and bringing new candidates into clinical development in the next two years.


 

MORE INSIDE POST